Tag: PVX108

Aravax

Aravax Doses First Patient in Phase 2 Peanut Allergy Clinical Trial 

PVX108 does not contain peanut proteins which put patients at risk of serious side effects.
Test Tubes

FDA Green Lights Phase 2 Trials of PVX108, a Novel Peptide-Driven...

Phase 2 study of candidate from Aravax will commence in the US and Australia.
Research

Aravax Presents Additional Positive Phase I Trial Results for PVX108, a...

Trial results demonstrate excellent PVX108 safety profile in patients with prior anaphylaxis and current asthma.
Researchers

Phase I Trial for New Peanut Allergy Immunotherapy Results in No...

Research details phase one study of peptide-based immunotherapy, which is designed to remove risks of acute reactions during treatment.
Researchers

Novel Peanut Allergy Vaccine Begins Phase I Clinical Trials

Vaccine uses peptides selected from parts of the peanut protein that do not cause life-threatening anaphylactic reactions.